NCT04892810Completed
Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
This cohort study compares immune response induced in two groups of small HCC patients treated by ablation (group1 RFA, group 2 MWA). Patients will benefit for tumoral and non tumoral biopsies prior to treatment and stepped peripheral blood samples juste before ablation and during the first month after.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 20 (actual)
- First submitted
- 3 May 2021
- Start date
- 3 Feb 2022
- Primary completion date
- 10 Jun 2026
- Lead sponsor
- University Hospital, Grenoble
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT04892810
What you commit to
- Study type: Observational
- Participants enrolled: 20
- From 3 Feb 2022 to the primary completion date, 10 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Fibrolamellar HCC
- Hepatocholangiocarcinoma
Who the study is looking for
- Histologically proven HCC for less than 3 months before ablation
- Decision of ablation treatment in multidisciplinary meeting
Age in the registry: 40 years to - · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Grenoble Alpes Coordinator of this site? Confirm its status | Grenoble | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.